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Abstract
Purpose This study aimed to develop an algorithm to
identify patients with CD, and quantify the clinical and
economic burden that patients with CD face compared to
CD-free controls.
Methods A retrospective cohort study of CD patients was
conducted in a large US commercial health plan database
between 1/1/2007 and 12/31/2011. A control group with no
evidence of CD during the same time was matched 1:3
based on demographics. Comorbidity rates were compared
using Poisson and health care costs were compared using
robust variance estimation.
Results A case-finding algorithm identified 877 CD
patients, who were matched to 2631 CD-free controls. The
age and sex distribution of the selected population matched
the known epidemiology of CD. CD patients were found to
have comorbidity rates that were two to five times higher
and health care costs that were four to seven times higher
than CD-free controls.
Conclusion An algorithm based on eight pituitary con-
ditions and procedures appeared to identify CD patients in
a claims database without a unique diagnosis code. Young
CD patients had high rates of comorbidities that are more
commonly observed in an older population (e.g., diabetes,
hypertension, and cardiovascular disease). Observed health
care costs were also high for CD patients compared to CD-
free controls, but may have been even higher if the sample
had included healthier controls with no health care use as
well. Earlier diagnosis, improved surgery success rates, and
better treatments may all help to reduce the chronic
comorbidity and high health care costs associated with CD.
Keywords Cushing’s disease  Case-finding algorithm 
Comorbidities  Health care costs
Introduction
Cushing’s disease (CD) is a rare and debilitating condition
that is caused by a pituitary adenoma secreting excessive
adrenocorticotropic hormone (ACTH). It occurs mainly in
young women of child-bearing age [1] and is one of several
causes of hypercortisolism (also known as Cushing’s syn-
drome). The signs and symptoms of hypercortisolism
include obesity, fatigue, depression, muscle weakness,
hypertension, headache, diabetes, easy bruising, stria, and
osteoporotic fractures. Many of these conditions are com-
mon in the general population, which often obscures CD
and delays its diagnosis [2]. Subsequently, with continued
exposure to high endogenous cortisol levels, health-related
quality of life (HRQoL) is impaired and the risk of pre-
mature death increases [2].
Although surgery and optimal follow-up may normalize
mortality, remission rates at best may range from 65 to
90 % and relapse is common [3]. Previously, effective
treatments were off-label, but recently some new medica-
tions have been approved and some off-label medications
are now being studied for approval [4]. If not treated
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adequately, the risk of morbidity and mortality associated
with CD may persist and remain high. Consequently, the
economic burden associated with CD may also be signifi-
cant resulting from its chronic nature and impact on major
metabolic systems (e.g., glucose and lipid regulation, car-
diovascular, immunity, skin, and skeletal). To date, there is
limited literature in the US comparing the comorbidities
and health care costs of CD patients and CD-free controls.
Analyzing administrative claims from a health care
database is a cost-effective way to study a rare disease such
as CD. Collected for billing purposes, health care claims
include codes for medical conditions and prescribed treat-
ments and procedures, which make them a valuable
resource for studying real-world treatment patterns, health
care outcomes and costs [5]. However, the International
Classification of Diseases, 9th Revision, Clinical Modifi-
cation (ICD-9-CM) system does not include a unique
diagnosis code for CD, which complicates the process of
identifying CD patients in claims. To contribute to the
literature, the objectives of this research were to (1)
develop an algorithm to identify patients with CD in an
administrative claims database without a unique diagnosis
code, and (2) quantify the clinical and economic burden
that patients with CD face compared to CD-free controls in
a large US managed care database.
Methods
Study design and sample
This was a retrospective cohort study using administrative
claims from a large health insurance database between July 1,
2006 and June 30, 2012 (study period). The database includes
over 12.9 million commercial health plan enrollees annually
with medical and pharmacy benefits. Health plans included in
the database are geographically diverse across the US.
Medical (professional and facility) claims in the database
include ICD-9-CM diagnosis and procedure codes, Current
Procedural Terminology, Version 4 (CPT-4) procedure
codes, Healthcare Common Procedure Coding System
(HCPCS) procedure codes, site of service codes, and health
plan- and patient-paid amounts. Outpatient pharmacy
claims include National Drug Codes (NDC) for dispensed
medications, dosage form, fill date, and health plan- and
patient-paid amounts. All administrative claims data are de-
identified and compliant with the provisions of the Health
Insurance Portability and Accountability Act of 1996.
Cushing’s disease case identification
An algorithm was developed using medical expert opinion
to identify patients with CD in administrative claims.
Starting with an ICD-9-CM diagnosis code for Cushing’s
syndrome (CS), the broader spectrum of etiologies
encompassing CD, two endocrinologists evaluated 18
pituitary conditions and procedures to distinguish CD from
CS. The result was to identify children (\18 years) and
adult commercial health plan enrollees as having CD if
they had (1) at least one medical claim with a CS diagnosis
code (ICD-9-CM: 255.0) and (2) at least one of eight
selected pituitary conditions and procedures (Table 1). CS
and pituitary diagnosis codes on medical claims from
laboratories and diagnostic testing centers were not
examined for selection, as they may have included ‘‘rule-
out’’ procedures for a diagnosis not yet confirmed. The
identification period was from January 1, 2007 through
December 31, 2011 and the index date was defined as the
first date for CS, a CD-related condition (pituitary tumor or
disorder), or CD-related procedure (hypophysectomy,
radiation, or bilateral inferior petrosal sinus sampling)
during the identification period. The CD-related condition
or procedure on the index date was defined as the index CD
event. Selected CD patients were required to be continu-
ously enrolled with medical and pharmacy benefits for
6 months before (pre-index period) and at least 6 months
after the index date (post-index period) until the earliest of
death (as evidenced by hospital discharge claims or Social
Security Administration death records), disenrollment from
the health plan, or the study cut-off date (June 30, 2012).
Disease-free control identification
Children and adult health plan enrollees without claims for
CS and CD-related conditions and procedures during the
study period were included in this study as CD-free con-
trols. Controls were required to have at least one medical
claim for any other condition during the identification
period, and were observed during a similar time period
starting in the same index year as the identified CD
patients. The index date for controls was defined as the first
claim date for a medical service during the identification
period. Each CD patient was matched to three randomly
selected CD-free controls by age, sex, geographic region,
and index year.
Measurements
Demographic and pre-index clinical characteristics
Demographic variables included age, sex, and the US
census region of the health plan. General comorbid con-
ditions were identified using the Clinical Classifications
Software managed by the Agency for Healthcare Research
and Quality (AHRQ) [6]. This software generates indicator
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variables for specific disease conditions based on the
presence of ICD-9-CM diagnosis codes in the database.
The top five comorbid conditions during the pre-index
period were identified for children and adults.
Clinical burden
Incident comorbidities and complications for CD patients
and CD-free controls were identified during the post-index
period. Incidence was defined as the first occurrence of a
medical claim for a comorbidity or complication during the
post-index period, given that no such medical claims were
present during the 6-month pre-index period. The selected
medical conditions were derived from a list presented in
Feelders [7] and Clayton [8].
Economic burden
Economic outcomes included all-cause health care
resource utilization and costs during the post-index period.
Costs were computed as the sum of health plan- and
patient-paid amounts for all inpatient and outpatient med-
ical services delivered during the post-index period, and
were adjusted for inflation to 2011 dollars using the annual
medical care component of the Consumer Price Index [9].
Per patient per month (PPPM) counts and costs of all-cause
health care resource utilization were computed to account
for variable follow-up.
Statistical analysis
All study variables were summarized descriptively. Cate-
gorical variables were summarized with frequencies and
percentages and continuous variables with means, standard
deviations (SD), and medians. Rao-Scott Chi square and
robust variance estimation were performed to assess group
differences in categorical and continuous measures,
respectively. Clustered p-values were calculated to control
for within-match correlation.
Incidence rates for the comorbidities and complications
were calculated by dividing the number of ‘‘new’’ cases
(i.e., where no such medical claims existed during the pre-
index period) by 100 person-years at risk. The time at risk
was calculated as the number of days from the index date
until the date of the first claim for the medical condition.
Disease rates between CD patients and CD-free controls
were compared using incidence rate ratios (IRR) and 95 %
confidence intervals (CI) from the Poisson distribution with
a logarithmic link function and logarithmic person-time
offset to account for the variable observation time.
All analyses were performed using SAS v9.2 (SAS
Institute, Cary, NC). A p value less than 0.05 and a 95 %
confidence interval not containing 1 were used to signify
statistical significance.
Results
A flow chart of the sample selection is presented in Fig. 1.
Of the approximately 27 million commercial health plan
enrollees in the database from January 1, 2007 through
December 31, 2011, 9994 had at least one medical claim
with a CS diagnosis code; of which 1467 (15 %) had a
pituitary condition or procedure suggestive of CD. After
applying the remaining selection criteria, a total of 877 CD
patients were matched to 2631 CD-free controls.
Demographic and pre-index clinical characteristics
Table 2 presents the demographic and pre-index clinical
characteristics. The mean age was 42 years as of the index
CD event, and 75 % were women. The geographic distri-
bution matched the health plan with 16 % in the Midwest,
37 % in the Northeast, 36 % in the South, and 10 % in the
West.
Among the top five AHRQ comorbidities identified
during the pre-index period, prevalence was 1.5–10 times
higher among CD patients than CD-free controls. The top 5
Table 1 Cushing disease-related conditions and procedures
Pituitary conditions Pituitary procedures
Pituitary neoplasm Hypophysectomy
Pituitary disorders: Cranial stereotactic radiosurgery
Hyperfunction Bilateral inferior petrosal sinus catheterization with cortisol or adrenocorticotropic hormone
samplingOther anterior pituitary disorder
Hypothalamic control of anterior pituitary
Syndromes of diencephalohypophyseal
origin
Diagnosis and procedure codes are shown in Supplement Table A
Pituitary (2016) 19:167–174 169
123
conditions differed between children and adults. The top
conditions among children with CD included: metabolic
disorders, non-traumatic neurological disorders, skin con-
ditions and psychiatric/mental disorders. The top conditions
among adults with CD included: urogenital disorders, non-
traumatic musculoskeletal disorders, endocrine disorders
(non-diabetes), and hypertension. Both children and adults
with CD had high proportions of respiratory infections (47
and 27 %, respectively) during the pre-index period. Total
observation time following the index CD event ranged from
6 months to 5.5 years, with a median of 2.4 years for CD
patients and 1.5 years for CD-free controls.
Incremental clinical burden
Incidence rate ratios in Table 3 show that rates of new
comorbidity claims remained high for CD patients fol-
lowing the index CD event. Compared to CD-free controls,
CD patients had five times the rate of osteoporosis and
diabetes, four times the rate of cardiovascular disease, liver
disease, and obesity, three times the rate of hypertension,
depression, and mood disorders, and twice the rate of
dyslipidemia, menstrual abnormalities, and acne. Among
children, few comorbidities and complications were
observed. At most, 13 children with CD and 5 CD-free
controls had claims for abnormal weight gain during the
post-index period (IRR 9.1, 95 % CI 2.9–28.4).
Incremental economic burden
Table 4 presents the mean PPPM counts and costs of health
care resource utilization during the post-index period. The
mean number of PPPM health care visits was two to four
times higher for CD patients than CD-free controls (am-
bulatory visits: 2.55 vs. 0.86, p\ 0.001; emergency
department visits: 0.12 vs. 0.04, p\ 0.001; and inpatient
admissions: 0.04 vs. 0.01, p\ 0.001). Total mean PPPM
all-cause health care costs were also higher for CD patients
than CD-free controls, with an average cost difference of
nearly $3000 ($3232 vs. $489, p\ 0.001). Total costs were
driven primarily by medical costs, which accounted for 87
and 79 % of total costs for CD patients and CD-free con-
trols, respectively. On average, medical costs were nearly
seven times higher for CD patients than CD-free controls
($2800 vs. $384, p\ 0.001), and average PPPM pharmacy
costs were four times higher for CD patients than CD-free
controls ($432 vs. $104, p\ 0.001).
Discussion
This retrospective analysis of 877 CD patients and 2631
matched CD-free controls was performed using adminis-
trative claims data from a large health plan database in the
United States. The study developed an algorithm to identify
Commercial health plan enrollees in 
Optum Research Database between
1/2007 – 12/2011
N=27,475,524
At least one Cushing Syndrome (CS)
diagnosis code (ICD-9-CM: 255.0)
N=9,994
No Cushing Syndrome (CS)
diagnosis codes (ICD-9-CM: 255.0)
N=27,465,530
Cushing Disease (CD) Cases




No CS, no pituitary conditions, and
no pituitary procedures
N=24,979
Final Analytic CD Cases
Continuously enrolled for 6 months
before and after first CS or CD claim
N=877
3:1 Matched CD-free Controls
Continuously enrolled for 6 months
before and after first claim during same
CD case index year
N=2,631
Fig. 1 Sample identification
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CD patients in the absence of a unique ICD-9 diagnosis code
and evaluated the incremental clinical and economic burden
of CD compared to CD-free controls. The age and sex dis-
tribution of the selected sample matched the known epi-
demiology of CD [4], suggesting that CD patients may be
identifiable in administrative claims using an algorithm based
onCD-related diagnosis and procedure codes. In addition, CD
patients were found to have a high proportion of comorbidity
during the 6-month pre-index period, suggesting that a num-
ber of CD patients were likely diagnosed with CD prior to
study entry. Claims data, collected for billing purposes, often
do not include key measures for clinical research such as the
date of diagnosis or patients’ health status. As a result, the
pituitary conditions and procedures used in this study to
identify CD patients may continue to be relevant and impor-
tant to consider even after the adoption of the new ICD-10
coding system, which will include for the first time a unique
diagnosis code for CD as well as other rare conditions.
During the post-index period, CD patients were found to
have higher rates of comorbidities and higher health care
resource utilization and costs than CD-free controls. In
fact, these young CD patients had comorbidities (e.g.,
diabetes, hypertension, and cardiovascular disease) and
associated costs that are more commonly observed in an
older population. Published data on the health and costs of
treating CD patients are limited in the US. Although our
research methods differed slightly, the findings reported
here are consistent with prior studies that in general show
CD is a debilitating condition associated with high
comorbidity and health care costs [10, 11].
The occurrence of multiple comorbidities along with
cortisol-induced anxiety and mood disorders can be dis-
tressing for anyone but especially so for patients with CD
in their prime reproductive and earning years. Appropriate
use of medical therapies to control hypercortisolism has
been shown to improve the quality of life for CD patients
[12]. However, with variable surgical remission rates
between 65 and 90 % [3], increasing the rate of cure with
the first surgery may have the highest impact for decreasing
future morbidity and costs.
Table 2 Demographics and pre-index clinical characteristics
Total (N = 3508) CD (N = 877) CD-free (N = 2631) p value
Sex, n (%)
Female 2640 (75.26) 660 (75.26) 1980 (75.26) –
Male 868 (24.74) 217 (24.74) 651 (24.74)
Age, n (%)
Children (1–17 years) 172 (4.90) 43 (4.90) 129 (4.90) –
Adults (18? years) 3336 (95.10) 834 (95.10) 2502 (95.10)
Age, years, mean ± SD 42 ± 14 42 ± 14 42 ± 14 –
Geographic location, n (%)
Midwest 564 (16.08) 141 (16.08) 423 (16.08) –
Northeast 1308 (37.29) 327 (37.29) 981 (37.29) –
South 1268 (36.15) 317 (36.15) 951 (36.15) –
West 368 (10.49) 92 (10.49) 276 (10.49) –
Top 5 pre-index AHRQ comorbidities for children, n (%)
Respiratory infections 58 (33.72) 20 (46.51) 38 (29.46) 0.051
Metabolic disorders 35 (20.35) 27 (62.79) 8 (6.20) \0.001
Neurological disorders (non-traumatic) 32 (18.60) 25 (58.14) 7 (5.43) \0.001
Skin conditions 28 (16.28) 18 (41.86) 10 (7.75) \0.001
Psychiatric/mental disorders 27 (15.70) 11 (25.58) 16 (12.40) 0.087
Top 5 pre-index AHRQ comorbidities for adults, n (%)
Urogenital disorders 1110 (33.27) 407 (48.80) 703 (28.10) \0.001
Musculoskeletal disorders (non-traumatic) 818 (24.52) 309 (37.05) 509 (20.34) \0.001
Endocrine disorders (non-diabetes) 693 (20.77) 492 (58.99) 201 (8.03) \0.001
Respiratory infections 664 (19.90) 225 (26.98) 439 (17.55) \0.001
Hypertension 662 (19.84) 278 (33.33) 384 (15.35) \0.001
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Limitations
There are several limitations to keep in mind when inter-
preting the results of this study. First, as with all studies
analyzing retrospective billing data, there are limits to how
well these data can accurately capture an individual’s
medical history. While the conditions and procedures used
to create the CD algorithm may meet face validity, medical
charts should also be examined to confirm the final CD
assignments. Without this confirmation, it is possible that
Table 3 Post-index CD-related comorbid conditions (incidence rates per 100 person-years)
















Vertebral fracture 14 2266 0.6177 9 4887 0.1841 3.6967 1.6069 8.5041
Pathologic fracture 10 2289 0.4368 1 4903 0.0204 19.2745 2.4300 152.8805
Muscle weakness 65 2163 3.0046 22 4861 0.4526 7.5682 4.5271 12.6522
Osteoporosis 138 1877 7.3520 67 4726 1.4176 4.9953 3.6709 6.7976
Cardiovascular
Cerebrovascular accident 32 2228 1.4363 9 4885 0.1842 7.7964 3.7640 16.1489
Cardiovascular disease 207 1569 13.1931 169 4404 3.8372 3.6866 2.9863 4.5511
Hypertension 223 1087 20.5111 295 3724 7.9207 2.9111 2.3901 3.5456
Acute myocardial infarction 12 2281 0.5260 6 4891 0.1227 4.2876 1.6038 11.4623
Endocrine/metabolic
Diabetes (incl. impaired glucose
tolerance)
172 1578 10.9009 103 4481 2.2984 5.2234 4.0193 6.7881
Dyslipidemia 232 1110 20.8984 405 3482 11.6299 2.0073 1.6807 2.3973
Menstrual abnormalitya 180 1088 16.5452 263 3038 8.6565 1.9608 1.6134 2.3829
Impaired libido/impotence 22 2218 0.9919 16 4875 0.3282 3.0768 1.6744 5.6540
Obesity 176 1701 10.3459 128 4561 2.8062 3.7265 2.9284 4.7423
Liver disease (acute or chronic) 141 1873 7.5295 94 4684 2.0069 4.0495 3.0834 5.3182
Elevated liver enzymes 34 2202 1.5443 30 4855 0.6180 2.9989 1.7910 5.0212
Malnutrition 20 2250 0.8889 6 4892 0.1226 7.2474 2.9002 18.1103
Mental health
Depression 171 1599 10.6916 185 4256 4.3467 2.6286 2.1130 3.2700
Cognitive impairment 20 2264 0.8836 4 4897 0.0817 13.7019 4.0339 46.5416
Anxiety 180 1714 10.5023 220 4236 5.1932 2.2551 1.8258 2.7855
Mood disorders 99 1906 5.1947 83 4633 1.7914 2.9922 2.2088 4.0533
Other
Acne 67 2088 3.2091 88 4697 1.8735 1.9325 1.3850 2.6964
Hirsutism 43 2123 2.0259 8 4892 0.1635 10.0839 4.7417 21.4449
Non-healing surgical would (proxy -
poor skin healing)
7 2290 0.3057 2 4903 0.0408 7.4928 1.8713 30.0014
Infections 143 1848 7.7382 173 4536 3.8141 2.1748 1.7170 2.7547
Pediatric conditionsb
Short stature 1 29,477 0.0034 0 91,964 0.0000 – – –
Delayed sexual development/puberty 3 36,392 0.0082 1 91,881 0.0011 5.0495 0.4568 55.8186
Precocious sexual development/
puberty
3 38,664 0.0078 0 92,165 0.0000 – – –
Abnormal weight gain 13 23,469 0.0554 5 89,296 0.0056 9.1316 2.9363 28.3983
Overweight 2 39,712 0.0050 1 91,123 0.0011 4.5892 0.4187 50.2984
Failure to thrive 1 39,029 0.0026 0 92,165 0.0000 – – –
a Females only, b Children only
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patients with ectopic CS and a petrosal sinus sampling
(IPSS), for example, may have been incorrectly included in
the CD sample.
Second, it is possible that this study underestimated the
clinical and economic burden of CD. The actual incidence
of comorbidity may be higher than observed as the date of
CD diagnosis is not available in administrative claims. CD
is difficult to diagnose and diagnosis can take on average
2–5 years [7]. As a result, additional comorbidities may
have been present prior to study entry but not yet attributed
to hypercortisolism. For example, diabetes at first may be
associated with being overweight, but later, as the intensity
of the hypercortisolism increases, realized to be a sign of
CD, which means claims during the pre-index period or
earlier may not have been properly identified as relating to
CD. Consequently, our cost estimates may be conservative
as well, as costs between the diagnosis and study entry
dates are not included and costs prior to the first claim for
CD may have been misattributed to other causes.
Third, the study included controls with at least one
medical visit during the identification period. Thus, our
control population may reflect a higher rate of comorbidity
and health care costs than if a healthier cohort with no
health care use was included in the study as well, which
suggests another reason the actual clinical and economic
burden of CD may be larger than observed.
Fourth, CD patients are typically women of childbearing
age and the societal costs of pregnancy delays and risks
associated with the comorbidities and complications of CD
are not included in this analysis. Instead, only the direct
medical costs of the health plans and patients enrolled with
one health insurer in the US are presented.
Fifth, the study data came from a commercially insured
managed care population and the results are primarily
applicable to patient populations who receive their care
through similar health delivery systems. The health plans
included in the database cover a wide geographic distri-
bution across the US, which suggest the results may be
generalizable to comparable managed care populations on
a national level.
Notwithstanding these limitations, the use of an
administrative claims database provided access to a large
and diverse patient population from which an adequate
sample of patients with CD, a rare disease, could be
identified and evaluated for real-world treatment patterns
on a national scale.
Conclusion
A case-finding algorithm based on eight pituitary condi-
tions and procedures appeared to identify CD patients in an
administrative claims database without a unique diagnosis
code, and the sex and age distribution of the selected
population matched the known epidemiology of CD. Fol-
lowing further validation, this case-finding algorithm may
be useful for other claims database studies.
Study findings suggest that compared to CD-free con-
trols, young CD patients have higher incidence rates of
comorbidities such as cardiovascular, endocrine, muscu-
loskeletal, and mental health conditions. Many of the
comorbidity rates were two to five times higher than the
matched controls. In addition, substantially higher health
care resource use and costs were observed for CD patients
compared to CD-free controls. Furthermore, even larger
cost differences may have been observed if the sample had
included healthier controls with no health care use as well.
Earlier diagnosis, improved surgery success rates of cure,
and better treatments may all help to reduce the chronic
comorbidity and high health care costs associated with CD.
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Table 4 Post-index per patient
per month (PPPM) count and
costs of all-cause health care
utilization
CD (N = 877) CD-free (N = 2631) p value
PPPM Count, mean (SD)
Ambulatory 2.55 (2.04) 0.86 (1.00) \0.001
Outpatient hospital 0.87 (1.03) 0.22 (0.39) \0.001
Physician office 1.76 (1.52) 0.66 (0.82) \0.001
Emergency department 0.12 (0.26) 0.04 (0.19) \0.001
Inpatient hospital 0.04 (0.09) 0.01 (0.03) \0.001
PPPM Costs, US$, mean (SD) [median]
Total all-cause health care costs 3232 (6958) [1433] 489 (1247) [184] \0.001
Medical costs 2800 (6788) [1067] 384 (1079) [121] \0.001
Pharmacy costs 432 (722) [162] 104 (515) [22] \0.001
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